Eagle Pharmaceuticals is a specialty pharmaceutical company, focusing on developing and commercializing injectable products primarily in the critical care and oncology areas. The Company offers argatroban for heparin-induced thrombocytopenia, Ryanodex for malignant hyperthermia, non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head and neck cancers/gastric adenocarcinoma, as well as Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.

Type
Public
HQ
Woodcliff Lake, US
Founded
2007
Size (employees)
77 (est)
Eagle Pharmaceuticals was founded in 2007 and is headquartered in Woodcliff Lake, US
Report incorrect company information

Key People/Management at Eagle Pharmaceuticals

Scott Tarriff

Scott Tarriff

Chief Executive Officer, Director
Pete Meyers

Pete Meyers

Chief Financial Officer
Steven Krill

Steven Krill

Executive Vice President and Chief Scientific Officer
John LaRocca

John LaRocca

Executive Vice President and General Counsel
Daniel OConnor

Daniel OConnor

Executive Vice President, Biologics and Corporate Development
Adrian Hepner

Adrian Hepner

Executive Vice President and Chief Medical Officer
Show more

Eagle Pharmaceuticals Office Locations

Eagle Pharmaceuticals has offices in Charlotte, Dallas, Los Angeles, Chicago and in 15 other locations
Woodcliff Lake, US (HQ)
50 Tice Blvd, Suite 315
Show all (19)
Report incorrect company information

Eagle Pharmaceuticals Financials and Metrics

Eagle Pharmaceuticals Financials

Eagle Pharmaceuticals's revenue was reported to be $236.71 m in FY, 2017
USD

Revenue (Q1, 2018)

46.6 m

Gross profit (Q1, 2018)

39.4 m

Gross profit margin (Q1, 2018), %

84.5%

Net income (Q1, 2018)

2.6 m

EBIT (Q1, 2018)

2.3 m

Market capitalization (15-May-2018)

979.1 m

Closing share price (15-May-2018)

66

Cash (31-Mar-2018)

95.7 m

EV

889.7 m
Eagle Pharmaceuticals's current market capitalization is $979.1 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

19.1 m66.2 m189.5 m236.7 m

Revenue growth, %

247%186%

Cost of goods sold

1.8 m33.7 m

Gross profit

187.7 m203 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

6 m5.7 m29.6 m40.9 m37.8 m76.8 m50.1 m46.6 m

Cost of goods sold

3.3 m3.8 m14.6 m11.5 m10.4 m10.8 m8.9 m7.2 m

Gross profit

2.7 m2 m15 m29.4 m27.4 m66 m41.2 m39.4 m

Gross profit Margin, %

44%35%51%72%72%86%82%85%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

34.9 m79.1 m52.8 m114.7 m

Accounts Receivable

12 m26.3 m42.2 m53.8 m

Inventories

1.2 m15 m11.4 m5.1 m

Current Assets

49.7 m122.3 m109.1 m188.7 m
Quarterly
USDQ1, 2017Q2, 2017Q1, 2018

Cash

27.7 m55.4 m95.7 m

Accounts Receivable

84.7 m53.2 m53.4 m

Inventories

3 m3.6 m6.1 m

Current Assets

123.6 m123.9 m168.8 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(18 m)2.6 m81.5 m51.9 m

Depreciation and Amortization

13 k932 k

Inventories

(1.3 m)(13.8 m)12.3 m(2.4 m)

Accounts Payable

2.9 m356 k10.7 m(8.5 m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(8.2 m)(10.2 m)(896 k)13.1 m12 m22.9 m2.6 m

Depreciation and Amortization

341 k

Inventories

329 k2 m2.3 m7.3 m7.8 m6.4 m7.1 m3 m(1 m)

Accounts Payable

2.5 m2.5 m5.4 m4.8 m14.1 m10.3 m11.4 m13.1 m19 m(2.6 m)
USDY, 2018

EV/EBIT

386 x

EV/CFO

180.8 x

Financial Leverage

1.4 x
Show all financial metrics
Report incorrect company information

Eagle Pharmaceuticals News and Updates

Report incorrect company information